Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

ICAAC 2014: Telaprevir and Boceprevir Have Limited Efficacy in Real-world Use

Hepatitis C treatment using the first-generation HCV protease inhibitors telaprevir (Incivek or Incivo) or boceprevir (Victrelis) cured only 71% of people with easier-to-treat HCV genotypes 1b, falling to 47% for those with genotype 1a, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC.

alt

Read more:

Vertex to Discontinue Sale of Telaprevir (Incivek) for Hepatitis C

Vertex Pharmaceuticals announced last week that it will stop selling its HCV protease inhibitor telaprevir (Incivek or Incivo) as of October 16, 2014. While the first generation direct-acting antivirals are more effective than pegylated interferon plus ribavirin alone, they are no match for newer drugs such as Gilead Sciences' sofosbuvir (Sovaldi) or AbbVie's forthcoming "3D" regimen in terms of efficacy or tolerability.

alt

Read more:

IDWeek 2013: Older People Respond Equally Well to Telaprevir Triple Therapy for Hepatitis C

Interferon-based therapy with telaprevir (Incivek or Incivo) produced a similar cure rate with no notable increase in side effects or treatment discontinuation for genotype 1 chronic hepatitis C patients over age 60, Japanese researchers reported at the second IDWeek conference held recently in San Francisco.

alt

Read more:

Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment

An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.

alt

Read more:

Telaprevir Triple Therapy Shows Activity Against HCV Genotype 4

The HCV protease inhibitor telaprevir (Incivek or Incivo) in combination with pegylated interferon and ribavirin reduced viral levels by more than 4 log in people with genotype 4 hepatitis C in a short Phase 2a study, researchers reported in the September 15, 2013 Journal of Infectious Diseases.

alt

Read more: